�ݺ�ߣshows by User: drvishwanathhesarur

�ݺ�ߣshows by User: drvishwanathhesarur / http://www.slideshare.net/images/logo.gif �ݺ�ߣshows by User: drvishwanathhesarur / Thu, 02 Apr 2015 06:50:28 GMT �ݺ�ߣShare feed for �ݺ�ߣshows by User: drvishwanathhesarur Treatment strategies in patients with statin intolerance /slideshow/treatment-strategies-in-patients-with-statin-intolerance/46574534 treatmentstrategiesinpatientswithstatinintolerance-150402065028-conversion-gate01
Statins are among the most prescribed drugs in the world and are first-line therapy in the management of hyperlipidemia. Their beneficial effects on cardiovascular morbidity and mortality have been demonstrated both in primary and in secondary prevention. They are generally safe, but in some patients, statin therapy is stopped because of intolerance to the drug that may result in muscle aches and weakness, gastrointestinal symptoms, liver enzyme abnormalities, or other nonspecific discomforts. The rate of reported statin-related events is about 5% to 10% in randomized, placebo controlled clinical trials.]]>
Statins are among the most prescribed drugs in the world and are first-line therapy in the management of hyperlipidemia. Their beneficial effects on cardiovascular morbidity and mortality have been demonstrated both in primary and in secondary prevention. They are generally safe, but in some patients, statin therapy is stopped because of intolerance to the drug that may result in muscle aches and weakness, gastrointestinal symptoms, liver enzyme abnormalities, or other nonspecific discomforts. The rate of reported statin-related events is about 5% to 10% in randomized, placebo controlled clinical trials.]]> Thu, 02 Apr 2015 06:50:28 GMT /slideshow/treatment-strategies-in-patients-with-statin-intolerance/46574534 drvishwanathhesarur@slideshare.net(drvishwanathhesarur) Treatment strategies in patients with statin intolerance drvishwanathhesarur Statins are among the most prescribed drugs in the world and are first-line therapy in the management of hyperlipidemia. Their beneficial effects on cardiovascular morbidity and mortality have been demonstrated both in primary and in secondary prevention. They are generally safe, but in some patients, statin therapy is stopped because of intolerance to the drug that may result in muscle aches and weakness, gastrointestinal symptoms, liver enzyme abnormalities, or other nonspecific discomforts. The rate of reported statin-related events is about 5% to 10% in randomized, placebo controlled clinical trials. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/treatmentstrategiesinpatientswithstatinintolerance-150402065028-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds" /> Statins are among the most prescribed drugs in the world and are first-line therapy in the management of hyperlipidemia. Their beneficial effects on cardiovascular morbidity and mortality have been demonstrated both in primary and in secondary prevention. They are generally safe, but in some patients, statin therapy is stopped because of intolerance to the drug that may result in muscle aches and weakness, gastrointestinal symptoms, liver enzyme abnormalities, or other nonspecific discomforts. The rate of reported statin-related events is about 5% to 10% in randomized, placebo controlled clinical trials.

Treatment strategies in patients with statin intolerance from Vishwanath Hesarur

]]> 1875 5 https://cdn.slidesharecdn.com/ss_thumbnails/treatmentstrategiesinpatientswithstatinintolerance-150402065028-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 The age, creatinine, and ejection fraction score to risk /slideshow/the-age-creatinine-and-ejection-fraction-score-to-risk/46574526 theagecreatinineandejectionfractionscoretorisk-150402065013-conversion-gate01
CTOs are the most challenging coronary lesions for PCI, with a success rate ranging from 55% to 100%. Successful PCI of CTOs is associated with improved long-term clinical outcomes compared with conservative management. Nevertheless, the clinical outcome even after successful recanalization remains worse compared with patients with non-CTO stenoses who underwent PCI.]]>
CTOs are the most challenging coronary lesions for PCI, with a success rate ranging from 55% to 100%. Successful PCI of CTOs is associated with improved long-term clinical outcomes compared with conservative management. Nevertheless, the clinical outcome even after successful recanalization remains worse compared with patients with non-CTO stenoses who underwent PCI.]]> Thu, 02 Apr 2015 06:50:13 GMT /slideshow/the-age-creatinine-and-ejection-fraction-score-to-risk/46574526 drvishwanathhesarur@slideshare.net(drvishwanathhesarur) The age, creatinine, and ejection fraction score to risk drvishwanathhesarur CTOs are the most challenging coronary lesions for PCI, with a success rate ranging from 55% to 100%. Successful PCI of CTOs is associated with improved long-term clinical outcomes compared with conservative management. Nevertheless, the clinical outcome even after successful recanalization remains worse compared with patients with non-CTO stenoses who underwent PCI. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/theagecreatinineandejectionfractionscoretorisk-150402065013-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds" /> CTOs are the most challenging coronary lesions for PCI, with a success rate ranging from 55% to 100%. Successful PCI of CTOs is associated with improved long-term clinical outcomes compared with conservative management. Nevertheless, the clinical outcome even after successful recanalization remains worse compared with patients with non-CTO stenoses who underwent PCI.

The age, creatinine, and ejection fraction score to risk from Vishwanath Hesarur

]]> 734 4 https://cdn.slidesharecdn.com/ss_thumbnails/theagecreatinineandejectionfractionscoretorisk-150402065013-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Riociguat for the treatment of pah /slideshow/riociguat-for-the-treatment-of-pah/46574510 riociguatforthetreatmentofpah-150402064955-conversion-gate01
New class of therapeutic agents called soluble guanylate cyclase (sGC) stimulators. Impairment of NO synthesis and signaling through the NO-sGC–cGMP pathway is involved in the pathogenesis of pulmonary hypertension. Dual mode of action, Directly stimulating sGC independently of NO, and Increasing the sensitivity of sGC to NO. vasorelaxation , antiproliferative and antifibrotic effects]]>
New class of therapeutic agents called soluble guanylate cyclase (sGC) stimulators. Impairment of NO synthesis and signaling through the NO-sGC–cGMP pathway is involved in the pathogenesis of pulmonary hypertension. Dual mode of action, Directly stimulating sGC independently of NO, and Increasing the sensitivity of sGC to NO. vasorelaxation , antiproliferative and antifibrotic effects]]> Thu, 02 Apr 2015 06:49:55 GMT /slideshow/riociguat-for-the-treatment-of-pah/46574510 drvishwanathhesarur@slideshare.net(drvishwanathhesarur) Riociguat for the treatment of pah drvishwanathhesarur New class of therapeutic agents called soluble guanylate cyclase (sGC) stimulators. Impairment of NO synthesis and signaling through the NO-sGC–cGMP pathway is involved in the pathogenesis of pulmonary hypertension. Dual mode of action, Directly stimulating sGC independently of NO, and Increasing the sensitivity of sGC to NO. vasorelaxation , antiproliferative and antifibrotic effects <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/riociguatforthetreatmentofpah-150402064955-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds" /> New class of therapeutic agents called soluble guanylate cyclase (sGC) stimulators. Impairment of NO synthesis and signaling through the NO-sGC–cGMP pathway is involved in the pathogenesis of pulmonary hypertension. Dual mode of action, Directly stimulating sGC independently of NO, and Increasing the sensitivity of sGC to NO. vasorelaxation , antiproliferative and antifibrotic effects

Riociguat for the treatment of pah from Vishwanath Hesarur

]]> 1308 4 https://cdn.slidesharecdn.com/ss_thumbnails/riociguatforthetreatmentofpah-150402064955-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Radiation dose reduction /slideshow/radiation-dose-reduction/46574491 radiationdosereduction-150402064920-conversion-gate01
Ionizing radiation makes invasive cardiology procedures such as coronary angiography, percutaneous coronary intervention (PCI), and electrophysiologic diagnostics and therapeutics possible . Radiation risks can be thought of as deterministic (effects after exceeding certain threshold, e.g., skin burns) or stochastic (a risk of an outcome is proportional to the dose received, e.g., malignancy or teratogenicity) . Reducing the radiation exposure in the cardiac catheterization laboratory is important, especially as procedures are becoming more complex .]]>
Ionizing radiation makes invasive cardiology procedures such as coronary angiography, percutaneous coronary intervention (PCI), and electrophysiologic diagnostics and therapeutics possible . Radiation risks can be thought of as deterministic (effects after exceeding certain threshold, e.g., skin burns) or stochastic (a risk of an outcome is proportional to the dose received, e.g., malignancy or teratogenicity) . Reducing the radiation exposure in the cardiac catheterization laboratory is important, especially as procedures are becoming more complex .]]> Thu, 02 Apr 2015 06:49:20 GMT /slideshow/radiation-dose-reduction/46574491 drvishwanathhesarur@slideshare.net(drvishwanathhesarur) Radiation dose reduction drvishwanathhesarur Ionizing radiation makes invasive cardiology procedures such as coronary angiography, percutaneous coronary intervention (PCI), and electrophysiologic diagnostics and therapeutics possible . Radiation risks can be thought of as deterministic (effects after exceeding certain threshold, e.g., skin burns) or stochastic (a risk of an outcome is proportional to the dose received, e.g., malignancy or teratogenicity) . Reducing the radiation exposure in the cardiac catheterization laboratory is important, especially as procedures are becoming more complex . <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/radiationdosereduction-150402064920-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds" /> Ionizing radiation makes invasive cardiology procedures such as coronary angiography, percutaneous coronary intervention (PCI), and electrophysiologic diagnostics and therapeutics possible . Radiation risks can be thought of as deterministic (effects after exceeding certain threshold, e.g., skin burns) or stochastic (a risk of an outcome is proportional to the dose received, e.g., malignancy or teratogenicity) . Reducing the radiation exposure in the cardiac catheterization laboratory is important, especially as procedures are becoming more complex .

Radiation dose reduction from Vishwanath Hesarur

]]> 1330 4 https://cdn.slidesharecdn.com/ss_thumbnails/radiationdosereduction-150402064920-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Pre hospital reduced-dose fibrinolysis followed by pci /slideshow/pre-hospital-reduceddose-fibrinolysis-followed-by-pci/46574473 pre-hospitalreduced-dosefibrinolysisfollowedbypci-150402064825-conversion-gate01
Extensive investigations of treatment strategies for patients with STEMIs have led to many improvements in care. Yet optimal treatment strategies for patients aged ≥75 years with STEMIs are much less clear, and many knowledge gaps remain. Age ≥75 years is an independent predictor of 30-day mortality in STEMI. Although this higher mortality risk generally would dictate more aggressive treatments, recent data have shown, for example, that <1/2 of patients aged ≥80 years with STEMIs are treated with any reperfusion therapies at all.]]>
Extensive investigations of treatment strategies for patients with STEMIs have led to many improvements in care. Yet optimal treatment strategies for patients aged ≥75 years with STEMIs are much less clear, and many knowledge gaps remain. Age ≥75 years is an independent predictor of 30-day mortality in STEMI. Although this higher mortality risk generally would dictate more aggressive treatments, recent data have shown, for example, that <1/2 of patients aged ≥80 years with STEMIs are treated with any reperfusion therapies at all.]]> Thu, 02 Apr 2015 06:48:24 GMT /slideshow/pre-hospital-reduceddose-fibrinolysis-followed-by-pci/46574473 drvishwanathhesarur@slideshare.net(drvishwanathhesarur) Pre hospital reduced-dose fibrinolysis followed by pci drvishwanathhesarur Extensive investigations of treatment strategies for patients with STEMIs have led to many improvements in care. Yet optimal treatment strategies for patients aged ≥75 years with STEMIs are much less clear, and many knowledge gaps remain. Age ≥75 years is an independent predictor of 30-day mortality in STEMI. Although this higher mortality risk generally would dictate more aggressive treatments, recent data have shown, for example, that <1/2 of patients aged ≥80 years with STEMIs are treated with any reperfusion therapies at all. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/pre-hospitalreduced-dosefibrinolysisfollowedbypci-150402064825-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds" /> Extensive investigations of treatment strategies for patients with STEMIs have led to many improvements in care. Yet optimal treatment strategies for patients aged ≥75 years with STEMIs are much less clear, and many knowledge gaps remain. Age ≥75 years is an independent predictor of 30-day mortality in STEMI. Although this higher mortality risk generally would dictate more aggressive treatments, recent data have shown, for example, that &lt;1/2 of patients aged ≥80 years with STEMIs are treated with any reperfusion therapies at all.

Pre hospital reduced-dose fibrinolysis followed by pci from Vishwanath Hesarur

]]> 576 3 https://cdn.slidesharecdn.com/ss_thumbnails/pre-hospitalreduced-dosefibrinolysisfollowedbypci-150402064825-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Nstemi /slideshow/nstemi-46574465/46574465 nstemi-150402064814-conversion-gate01
Risk stratification remains central to implement appropriate therapeutic measures for patients with NSTEMI. The ECG provides rapid risk assessment for patients presenting with chest pain that permits their allocation to appropriate management algorithms to improve the outcomes]]>
Risk stratification remains central to implement appropriate therapeutic measures for patients with NSTEMI. The ECG provides rapid risk assessment for patients presenting with chest pain that permits their allocation to appropriate management algorithms to improve the outcomes]]> Thu, 02 Apr 2015 06:48:14 GMT /slideshow/nstemi-46574465/46574465 drvishwanathhesarur@slideshare.net(drvishwanathhesarur) Nstemi drvishwanathhesarur Risk stratification remains central to implement appropriate therapeutic measures for patients with NSTEMI. The ECG provides rapid risk assessment for patients presenting with chest pain that permits their allocation to appropriate management algorithms to improve the outcomes <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/nstemi-150402064814-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds" /> Risk stratification remains central to implement appropriate therapeutic measures for patients with NSTEMI. The ECG provides rapid risk assessment for patients presenting with chest pain that permits their allocation to appropriate management algorithms to improve the outcomes

Nstemi from Vishwanath Hesarur

]]> 1637 5 https://cdn.slidesharecdn.com/ss_thumbnails/nstemi-150402064814-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Monocyte chemoattractant protein 1 /slideshow/monocyte-chemoattractant-protein-1/46574452 monocytechemoattractantprotein-1-150402064758-conversion-gate01
Inflammation plays a crucial role in the initiation and progression of atherosclerotic disease. Monocyte chemoattractant protein-1 (MCP-1) is a member of the C-C chemokine family that is produced by monocytes or macrophages, smooth muscle cells, and endothelial cells within atherosclerotic plaques. In addition to its established role in the pathogenesis of atherosclerotic disease progression and plaque rupture, MCP-1 is also involved in the reparative response, such as arteriolar remodeling and restenosis after an acute coronary event.]]>
Inflammation plays a crucial role in the initiation and progression of atherosclerotic disease. Monocyte chemoattractant protein-1 (MCP-1) is a member of the C-C chemokine family that is produced by monocytes or macrophages, smooth muscle cells, and endothelial cells within atherosclerotic plaques. In addition to its established role in the pathogenesis of atherosclerotic disease progression and plaque rupture, MCP-1 is also involved in the reparative response, such as arteriolar remodeling and restenosis after an acute coronary event.]]> Thu, 02 Apr 2015 06:47:58 GMT /slideshow/monocyte-chemoattractant-protein-1/46574452 drvishwanathhesarur@slideshare.net(drvishwanathhesarur) Monocyte chemoattractant protein 1 drvishwanathhesarur Inflammation plays a crucial role in the initiation and progression of atherosclerotic disease. Monocyte chemoattractant protein-1 (MCP-1) is a member of the C-C chemokine family that is produced by monocytes or macrophages, smooth muscle cells, and endothelial cells within atherosclerotic plaques. In addition to its established role in the pathogenesis of atherosclerotic disease progression and plaque rupture, MCP-1 is also involved in the reparative response, such as arteriolar remodeling and restenosis after an acute coronary event. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/monocytechemoattractantprotein-1-150402064758-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds" /> Inflammation plays a crucial role in the initiation and progression of atherosclerotic disease. Monocyte chemoattractant protein-1 (MCP-1) is a member of the C-C chemokine family that is produced by monocytes or macrophages, smooth muscle cells, and endothelial cells within atherosclerotic plaques. In addition to its established role in the pathogenesis of atherosclerotic disease progression and plaque rupture, MCP-1 is also involved in the reparative response, such as arteriolar remodeling and restenosis after an acute coronary event.

Monocyte chemoattractant protein 1 from Vishwanath Hesarur

]]> 721 3 https://cdn.slidesharecdn.com/ss_thumbnails/monocytechemoattractantprotein-1-150402064758-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Energy drink /slideshow/energy-drink-46574445/46574445 energydrink-150402064740-conversion-gate01
The rapid increase in energy drink (ED) consumption has stimulated growing public concern with adverse events related to ED consumption. The US Substance Abuse Services and Mental Health Administration has reported that over a 4-year period from 2007 to 2011, emergency department visits related to EDs more than doubled to >20,000 visits annually. Most of the adverse effects and toxicities associated with EDs have been attributed to the high caffeine content of EDs.]]>
The rapid increase in energy drink (ED) consumption has stimulated growing public concern with adverse events related to ED consumption. The US Substance Abuse Services and Mental Health Administration has reported that over a 4-year period from 2007 to 2011, emergency department visits related to EDs more than doubled to >20,000 visits annually. Most of the adverse effects and toxicities associated with EDs have been attributed to the high caffeine content of EDs.]]> Thu, 02 Apr 2015 06:47:40 GMT /slideshow/energy-drink-46574445/46574445 drvishwanathhesarur@slideshare.net(drvishwanathhesarur) Energy drink drvishwanathhesarur The rapid increase in energy drink (ED) consumption has stimulated growing public concern with adverse events related to ED consumption. The US Substance Abuse Services and Mental Health Administration has reported that over a 4-year period from 2007 to 2011, emergency department visits related to EDs more than doubled to >20,000 visits annually. Most of the adverse effects and toxicities associated with EDs have been attributed to the high caffeine content of EDs. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/energydrink-150402064740-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds" /> The rapid increase in energy drink (ED) consumption has stimulated growing public concern with adverse events related to ED consumption. The US Substance Abuse Services and Mental Health Administration has reported that over a 4-year period from 2007 to 2011, emergency department visits related to EDs more than doubled to >20,000 visits annually. Most of the adverse effects and toxicities associated with EDs have been attributed to the high caffeine content of EDs.

Energy drink from Vishwanath Hesarur

]]> 1154 7 https://cdn.slidesharecdn.com/ss_thumbnails/energydrink-150402064740-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Dissolution trial /slideshow/dissolution-trial/46574438 dissolutiontrial-150402064727-conversion-gate01
Thrombus aspiration during percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) is said to reduce PCI-induced distal occlusion. In an attempt to enhance its effectiveness, thrombus aspiration is often coupled with glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors, although conflicting results with this strategy have been reported. GP IIb/IIIa antagonists inhibit the final common pathway that leads to platelet aggregation and leukocyte plugging, which are the main components of fresh thrombi.]]>
Thrombus aspiration during percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) is said to reduce PCI-induced distal occlusion. In an attempt to enhance its effectiveness, thrombus aspiration is often coupled with glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors, although conflicting results with this strategy have been reported. GP IIb/IIIa antagonists inhibit the final common pathway that leads to platelet aggregation and leukocyte plugging, which are the main components of fresh thrombi.]]> Thu, 02 Apr 2015 06:47:26 GMT /slideshow/dissolution-trial/46574438 drvishwanathhesarur@slideshare.net(drvishwanathhesarur) Dissolution trial drvishwanathhesarur Thrombus aspiration during percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) is said to reduce PCI-induced distal occlusion. In an attempt to enhance its effectiveness, thrombus aspiration is often coupled with glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors, although conflicting results with this strategy have been reported. GP IIb/IIIa antagonists inhibit the final common pathway that leads to platelet aggregation and leukocyte plugging, which are the main components of fresh thrombi. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/dissolutiontrial-150402064727-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds" /> Thrombus aspiration during percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) is said to reduce PCI-induced distal occlusion. In an attempt to enhance its effectiveness, thrombus aspiration is often coupled with glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors, although conflicting results with this strategy have been reported. GP IIb/IIIa antagonists inhibit the final common pathway that leads to platelet aggregation and leukocyte plugging, which are the main components of fresh thrombi.

Dissolution trial from Vishwanath Hesarur

]]> 580 3 https://cdn.slidesharecdn.com/ss_thumbnails/dissolutiontrial-150402064727-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Defer stemi /slideshow/defer-stemi/46574417 defer-stemi-150402064652-conversion-gate01
Primary PCI with stenting immediately after coronary reperfusion salvage procedures jeopardizes myocardium, improves prognosis, and is the current standard of care for acute STEMI . No-reflow is defined as an acute reduction in myocardial blood flow despite a patent epicardial coronary artery . The pathophysiology of no-reflow involves microvascular obstruction secondary to distal embolization of clot, microvascular spasm, and thrombosis . No-reflow occurs in ~10% of cases of primary PCI and is associated with patient characteristics such as advanced age and delayed presentation and coronary characteristics such as a completely occluded culprit artery and heavy thrombus burden .]]>
Primary PCI with stenting immediately after coronary reperfusion salvage procedures jeopardizes myocardium, improves prognosis, and is the current standard of care for acute STEMI . No-reflow is defined as an acute reduction in myocardial blood flow despite a patent epicardial coronary artery . The pathophysiology of no-reflow involves microvascular obstruction secondary to distal embolization of clot, microvascular spasm, and thrombosis . No-reflow occurs in ~10% of cases of primary PCI and is associated with patient characteristics such as advanced age and delayed presentation and coronary characteristics such as a completely occluded culprit artery and heavy thrombus burden .]]> Thu, 02 Apr 2015 06:46:52 GMT /slideshow/defer-stemi/46574417 drvishwanathhesarur@slideshare.net(drvishwanathhesarur) Defer stemi drvishwanathhesarur Primary PCI with stenting immediately after coronary reperfusion salvage procedures jeopardizes myocardium, improves prognosis, and is the current standard of care for acute STEMI . No-reflow is defined as an acute reduction in myocardial blood flow despite a patent epicardial coronary artery . The pathophysiology of no-reflow involves microvascular obstruction secondary to distal embolization of clot, microvascular spasm, and thrombosis . No-reflow occurs in ~10% of cases of primary PCI and is associated with patient characteristics such as advanced age and delayed presentation and coronary characteristics such as a completely occluded culprit artery and heavy thrombus burden . <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/defer-stemi-150402064652-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds" /> Primary PCI with stenting immediately after coronary reperfusion salvage procedures jeopardizes myocardium, improves prognosis, and is the current standard of care for acute STEMI . No-reflow is defined as an acute reduction in myocardial blood flow despite a patent epicardial coronary artery . The pathophysiology of no-reflow involves microvascular obstruction secondary to distal embolization of clot, microvascular spasm, and thrombosis . No-reflow occurs in ~10% of cases of primary PCI and is associated with patient characteristics such as advanced age and delayed presentation and coronary characteristics such as a completely occluded culprit artery and heavy thrombus burden .

Defer stemi from Vishwanath Hesarur

]]> 1231 1 https://cdn.slidesharecdn.com/ss_thumbnails/defer-stemi-150402064652-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Cvs & t2 dm /drvishwanathhesarur/cvs-t2-dm cvst2dm-150402064638-conversion-gate01
]]>
]]> Thu, 02 Apr 2015 06:46:38 GMT /drvishwanathhesarur/cvs-t2-dm drvishwanathhesarur@slideshare.net(drvishwanathhesarur) Cvs & t2 dm drvishwanathhesarur <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/cvst2dm-150402064638-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds" />

Cvs & t2 dm from Vishwanath Hesarur

]]> 818 8 https://cdn.slidesharecdn.com/ss_thumbnails/cvst2dm-150402064638-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 ��鰿��ʱ��մ��ձ��ձᷡ�鴡�ʳ��I��ʴ��ձ��ճ��±��ձ��ѱʴ��鷡��鷡��󱫱��ձ��A��䱫�շ��䰿�鰿��۱��ٸ鰿�ѷ��:��鷡��ճ��F�鰿��ձᷡ��-��䳧��հ䰿�ѷ��鷡�ұ��ո�� /slideshow/chronic-46574356/46574356 chronic-150402064421-conversion-gate01
Chronic use of aspirin and statin may reduce the risk of subsequent MI and improve outcome in patients with documented IHD or in patients at high risk of a first cardiovascular event. Moreover, previous aspirin & statin therapy may interfere with the clinical presentation of acute MI, with a higher incidence of NSTEMI as compared to STEMI.]]>
Chronic use of aspirin and statin may reduce the risk of subsequent MI and improve outcome in patients with documented IHD or in patients at high risk of a first cardiovascular event. Moreover, previous aspirin & statin therapy may interfere with the clinical presentation of acute MI, with a higher incidence of NSTEMI as compared to STEMI.]]> Thu, 02 Apr 2015 06:44:21 GMT /slideshow/chronic-46574356/46574356 drvishwanathhesarur@slideshare.net(drvishwanathhesarur) ��鰿��ʱ��մ��ձ��ձᷡ�鴡�ʳ��I��ʴ��ձ��ճ��±��ձ��ѱʴ��鷡��鷡��󱫱��ձ��A��䱫�շ��䰿�鰿��۱��ٸ鰿�ѷ��:��鷡��ճ��F�鰿��ձᷡ��-��䳧��հ䰿�ѷ��鷡�ұ��ո�� drvishwanathhesarur Chronic use of aspirin and statin may reduce the risk of subsequent MI and improve outcome in patients with documented IHD or in patients at high risk of a first cardiovascular event. Moreover, previous aspirin & statin therapy may interfere with the clinical presentation of acute MI, with a higher incidence of NSTEMI as compared to STEMI. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/chronic-150402064421-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds" /> Chronic use of aspirin and statin may reduce the risk of subsequent MI and improve outcome in patients with documented IHD or in patients at high risk of a first cardiovascular event. Moreover, previous aspirin & statin therapy may interfere with the clinical presentation of acute MI, with a higher incidence of NSTEMI as compared to STEMI.

CHRONIC ASPIRIN AND STATIN THERAPY IN PATIENTS WITH IMPAIRED RENAL FUNCTION AND ACUTE CORONARY SYNDROMES: RESULTS FROM THE IN-ACS OUTCOME REGISTRY from Vishwanath Hesarur

]]> 567 3 https://cdn.slidesharecdn.com/ss_thumbnails/chronic-150402064421-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Bivalirudin in acute coronary syndromes and percutaneous coronary /slideshow/bivalirudin-in-acute-coronary-syndromes-and-percutaneous-coronary/46574331 bivalirudininacutecoronarysyndromesandpercutaneouscoronary-150402064340-conversion-gate01
Anti-thrombotic therapy remains a cornerstone in per-cutaneous coronary intervention (PCI) and acute coronary syndrome (ACS) management. The search for newer anti-thrombotic drugs is ongoing with the goal to achieve an agent which leads to less bleeding complications without a reduction or indeed improvement in clinical efficacy, resulting in net clinical benefit. This is because major bleeding remains a significant risk factor for mortality following PCI with higher 30 days and one year mortality reported in numerous studies . Bleeding is associated with a five-fold increase in mor-tality and higher risk of myocardial infarction, stroke and stent thrombosis in ACS .]]>
Anti-thrombotic therapy remains a cornerstone in per-cutaneous coronary intervention (PCI) and acute coronary syndrome (ACS) management. The search for newer anti-thrombotic drugs is ongoing with the goal to achieve an agent which leads to less bleeding complications without a reduction or indeed improvement in clinical efficacy, resulting in net clinical benefit. This is because major bleeding remains a significant risk factor for mortality following PCI with higher 30 days and one year mortality reported in numerous studies . Bleeding is associated with a five-fold increase in mor-tality and higher risk of myocardial infarction, stroke and stent thrombosis in ACS .]]> Thu, 02 Apr 2015 06:43:40 GMT /slideshow/bivalirudin-in-acute-coronary-syndromes-and-percutaneous-coronary/46574331 drvishwanathhesarur@slideshare.net(drvishwanathhesarur) Bivalirudin in acute coronary syndromes and percutaneous coronary drvishwanathhesarur Anti-thrombotic therapy remains a cornerstone in per-cutaneous coronary intervention (PCI) and acute coronary syndrome (ACS) management. The search for newer anti-thrombotic drugs is ongoing with the goal to achieve an agent which leads to less bleeding complications without a reduction or indeed improvement in clinical efficacy, resulting in net clinical benefit. This is because major bleeding remains a significant risk factor for mortality following PCI with higher 30 days and one year mortality reported in numerous studies . Bleeding is associated with a five-fold increase in mor-tality and higher risk of myocardial infarction, stroke and stent thrombosis in ACS . <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/bivalirudininacutecoronarysyndromesandpercutaneouscoronary-150402064340-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds" /> Anti-thrombotic therapy remains a cornerstone in per-cutaneous coronary intervention (PCI) and acute coronary syndrome (ACS) management. The search for newer anti-thrombotic drugs is ongoing with the goal to achieve an agent which leads to less bleeding complications without a reduction or indeed improvement in clinical efficacy, resulting in net clinical benefit. This is because major bleeding remains a significant risk factor for mortality following PCI with higher 30 days and one year mortality reported in numerous studies . Bleeding is associated with a five-fold increase in mor-tality and higher risk of myocardial infarction, stroke and stent thrombosis in ACS .

Bivalirudin in acute coronary syndromes and percutaneous coronary from Vishwanath Hesarur

]]> 699 3 https://cdn.slidesharecdn.com/ss_thumbnails/bivalirudininacutecoronarysyndromesandpercutaneouscoronary-150402064340-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 CARDIOVASCULAR DISEASE AND DIABETES /slideshow/cardiovascular-disease-and-diabetes/46574242 cvsdm-150402063915-conversion-gate01
Diabetes mellitus (DM) refers to a group of common metabolic disorders that share the phenotype of hyperglycemia. Several distinct types of DM are caused by a complex interaction of genetics and environmental factors. Depending on the etiology of the DM, factors contributing to hyperglycemia include reduced insulin secretion, decreased glucose utilization, and increased glucose production. The metabolic dysregulation associated with DM causes secondary pathophysiologic changes in multiple organ systems that impose a tremendous burden on the individual with diabetes and on the health care system.]]>
Diabetes mellitus (DM) refers to a group of common metabolic disorders that share the phenotype of hyperglycemia. Several distinct types of DM are caused by a complex interaction of genetics and environmental factors. Depending on the etiology of the DM, factors contributing to hyperglycemia include reduced insulin secretion, decreased glucose utilization, and increased glucose production. The metabolic dysregulation associated with DM causes secondary pathophysiologic changes in multiple organ systems that impose a tremendous burden on the individual with diabetes and on the health care system.]]> Thu, 02 Apr 2015 06:39:15 GMT /slideshow/cardiovascular-disease-and-diabetes/46574242 drvishwanathhesarur@slideshare.net(drvishwanathhesarur) CARDIOVASCULAR DISEASE AND DIABETES drvishwanathhesarur Diabetes mellitus (DM) refers to a group of common metabolic disorders that share the phenotype of hyperglycemia. Several distinct types of DM are caused by a complex interaction of genetics and environmental factors. Depending on the etiology of the DM, factors contributing to hyperglycemia include reduced insulin secretion, decreased glucose utilization, and increased glucose production. The metabolic dysregulation associated with DM causes secondary pathophysiologic changes in multiple organ systems that impose a tremendous burden on the individual with diabetes and on the health care system. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/cvsdm-150402063915-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds" /> Diabetes mellitus (DM) refers to a group of common metabolic disorders that share the phenotype of hyperglycemia. Several distinct types of DM are caused by a complex interaction of genetics and environmental factors. Depending on the etiology of the DM, factors contributing to hyperglycemia include reduced insulin secretion, decreased glucose utilization, and increased glucose production. The metabolic dysregulation associated with DM causes secondary pathophysiologic changes in multiple organ systems that impose a tremendous burden on the individual with diabetes and on the health care system.

CARDIOVASCULAR DISEASE AND DIABETES from Vishwanath Hesarur

]]> 22440 26 https://cdn.slidesharecdn.com/ss_thumbnails/cvsdm-150402063915-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 FRACTIONAL FLOW RESERVE /slideshow/fractional-flow-reserve/46574188 fractionalflowreserve-150402063718-conversion-gate01
Based on the principle that the distal coronary pressure measured during vasodilation is directly proportional to maximum vasodilated perfusion. FFR is defined as the ratio of maximum blood flow in a stenotic artery to maximum blood flow in the same artery if there were no stenosis. FFR is simply calculated as a ratio of mean pressure distal to a stenosis (Pd) to the mean pressure proximal stenosis, that is the mean pressure in the aorta (Pa), during maximal hyperaemia.]]>
Based on the principle that the distal coronary pressure measured during vasodilation is directly proportional to maximum vasodilated perfusion. FFR is defined as the ratio of maximum blood flow in a stenotic artery to maximum blood flow in the same artery if there were no stenosis. FFR is simply calculated as a ratio of mean pressure distal to a stenosis (Pd) to the mean pressure proximal stenosis, that is the mean pressure in the aorta (Pa), during maximal hyperaemia.]]> Thu, 02 Apr 2015 06:37:18 GMT /slideshow/fractional-flow-reserve/46574188 drvishwanathhesarur@slideshare.net(drvishwanathhesarur) FRACTIONAL FLOW RESERVE drvishwanathhesarur Based on the principle that the distal coronary pressure measured during vasodilation is directly proportional to maximum vasodilated perfusion. FFR is defined as the ratio of maximum blood flow in a stenotic artery to maximum blood flow in the same artery if there were no stenosis. FFR is simply calculated as a ratio of mean pressure distal to a stenosis (Pd) to the mean pressure proximal stenosis, that is the mean pressure in the aorta (Pa), during maximal hyperaemia. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/fractionalflowreserve-150402063718-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds" /> Based on the principle that the distal coronary pressure measured during vasodilation is directly proportional to maximum vasodilated perfusion. FFR is defined as the ratio of maximum blood flow in a stenotic artery to maximum blood flow in the same artery if there were no stenosis. FFR is simply calculated as a ratio of mean pressure distal to a stenosis (Pd) to the mean pressure proximal stenosis, that is the mean pressure in the aorta (Pa), during maximal hyperaemia.

FRACTIONAL FLOW RESERVE from Vishwanath Hesarur

]]> 18962 10 https://cdn.slidesharecdn.com/ss_thumbnails/fractionalflowreserve-150402063718-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 ENDOMYOCARDIAL FIBROSIS /slideshow/endomyocardial-fibrosis/46574094 endomyocardialfibrosis-150402063320-conversion-gate01
Endomyocardial fibrosis (EMF) is a disease that is characterized by fibrosis of the apical endocardium of the right ventricle (RV), left ventricle (LV), or both. The clinical manifestations are largely related to the consequences of restrictive ventricular filling, including left and right sided heart failure. The heart failure is associated with atrioventricular-valve regurgitation. Endomyocardial fibrosis is a major cause of illness and death in areas where it is endemic, and in its severest form carries a very poor prognosis, with an estimated survival of 2 years after diagnosis.]]>
Endomyocardial fibrosis (EMF) is a disease that is characterized by fibrosis of the apical endocardium of the right ventricle (RV), left ventricle (LV), or both. The clinical manifestations are largely related to the consequences of restrictive ventricular filling, including left and right sided heart failure. The heart failure is associated with atrioventricular-valve regurgitation. Endomyocardial fibrosis is a major cause of illness and death in areas where it is endemic, and in its severest form carries a very poor prognosis, with an estimated survival of 2 years after diagnosis.]]> Thu, 02 Apr 2015 06:33:20 GMT /slideshow/endomyocardial-fibrosis/46574094 drvishwanathhesarur@slideshare.net(drvishwanathhesarur) ENDOMYOCARDIAL FIBROSIS drvishwanathhesarur Endomyocardial fibrosis (EMF) is a disease that is characterized by fibrosis of the apical endocardium of the right ventricle (RV), left ventricle (LV), or both. The clinical manifestations are largely related to the consequences of restrictive ventricular filling, including left and right sided heart failure. The heart failure is associated with atrioventricular-valve regurgitation. Endomyocardial fibrosis is a major cause of illness and death in areas where it is endemic, and in its severest form carries a very poor prognosis, with an estimated survival of 2 years after diagnosis. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/endomyocardialfibrosis-150402063320-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds" /> Endomyocardial fibrosis (EMF) is a disease that is characterized by fibrosis of the apical endocardium of the right ventricle (RV), left ventricle (LV), or both. The clinical manifestations are largely related to the consequences of restrictive ventricular filling, including left and right sided heart failure. The heart failure is associated with atrioventricular-valve regurgitation. Endomyocardial fibrosis is a major cause of illness and death in areas where it is endemic, and in its severest form carries a very poor prognosis, with an estimated survival of 2 years after diagnosis.

ENDOMYOCARDIAL FIBROSIS from Vishwanath Hesarur

]]> 10052 10 https://cdn.slidesharecdn.com/ss_thumbnails/endomyocardialfibrosis-150402063320-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 TOTAL ANOMALOUS PULMONARY VENOUS CONNECTION (TAPVC) /slideshow/total-anomalous-pulmonary-venous-connection-tapvc/46574092 totalanomalouspulmonaryvenousconnection2-150402063318-conversion-gate01
TAPVC defines the anomaly in which the pulmonary veins have no connection with the left atrium. Rather, the pulmonary veins connect directly to one of the systemic veins (TAPVC) or drain in to right atrium. A PFO or ASD is present essentially in those who survive after birth When pulmonary veins drain anomalously into the right atrium either because of complete absence of the interatrial septum or malattachment of the septum primum , then it is known as total anomalous pulmonary venous drainage. When some or all of the pulmonary veins drain anomalously in to RA or its tributaries without being abnormally connected, the terms partially anomalous pulmonary venous drainage (PAPVD) or totally anomalous pulmonary venous drainage (TAPVD) with normal pulmonary venous connections are used.]]>
TAPVC defines the anomaly in which the pulmonary veins have no connection with the left atrium. Rather, the pulmonary veins connect directly to one of the systemic veins (TAPVC) or drain in to right atrium. A PFO or ASD is present essentially in those who survive after birth When pulmonary veins drain anomalously into the right atrium either because of complete absence of the interatrial septum or malattachment of the septum primum , then it is known as total anomalous pulmonary venous drainage. When some or all of the pulmonary veins drain anomalously in to RA or its tributaries without being abnormally connected, the terms partially anomalous pulmonary venous drainage (PAPVD) or totally anomalous pulmonary venous drainage (TAPVD) with normal pulmonary venous connections are used.]]> Thu, 02 Apr 2015 06:33:18 GMT /slideshow/total-anomalous-pulmonary-venous-connection-tapvc/46574092 drvishwanathhesarur@slideshare.net(drvishwanathhesarur) TOTAL ANOMALOUS PULMONARY VENOUS CONNECTION (TAPVC) drvishwanathhesarur TAPVC defines the anomaly in which the pulmonary veins have no connection with the left atrium. Rather, the pulmonary veins connect directly to one of the systemic veins (TAPVC) or drain in to right atrium. A PFO or ASD is present essentially in those who survive after birth When pulmonary veins drain anomalously into the right atrium either because of complete absence of the interatrial septum or malattachment of the septum primum , then it is known as total anomalous pulmonary venous drainage. When some or all of the pulmonary veins drain anomalously in to RA or its tributaries without being abnormally connected, the terms partially anomalous pulmonary venous drainage (PAPVD) or totally anomalous pulmonary venous drainage (TAPVD) with normal pulmonary venous connections are used. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/totalanomalouspulmonaryvenousconnection2-150402063318-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds" /> TAPVC defines the anomaly in which the pulmonary veins have no connection with the left atrium. Rather, the pulmonary veins connect directly to one of the systemic veins (TAPVC) or drain in to right atrium. A PFO or ASD is present essentially in those who survive after birth When pulmonary veins drain anomalously into the right atrium either because of complete absence of the interatrial septum or malattachment of the septum primum , then it is known as total anomalous pulmonary venous drainage. When some or all of the pulmonary veins drain anomalously in to RA or its tributaries without being abnormally connected, the terms partially anomalous pulmonary venous drainage (PAPVD) or totally anomalous pulmonary venous drainage (TAPVD) with normal pulmonary venous connections are used.

TOTAL ANOMALOUS PULMONARY VENOUS CONNECTION (TAPVC) from Vishwanath Hesarur

]]> 21441 11 https://cdn.slidesharecdn.com/ss_thumbnails/totalanomalouspulmonaryvenousconnection2-150402063318-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Cardiac transplantation /slideshow/cardiac-transplantation-44128592/44128592 cardiactransplantation-150201093806-conversion-gate02
A heart transplant, or a cardiac transplant, is a surgical transplant procedure performed on patients with end-stage heart failure or severe coronary artery disease. As of 2008 the most common procedure is to take a working heart from a recently deceased organ donor (cadaveric allograft) and implant it into the patient. The patient's own heart is either removed (orthotopic procedure) or, less commonly, left in place to support the donor heart (heterotopic procedure). Post-operation survival periods average 15 years. Heart transplantation is not considered to be a cure for heart disease, but a life-saving treatment intended to improve the quality of life for recipients]]>
A heart transplant, or a cardiac transplant, is a surgical transplant procedure performed on patients with end-stage heart failure or severe coronary artery disease. As of 2008 the most common procedure is to take a working heart from a recently deceased organ donor (cadaveric allograft) and implant it into the patient. The patient's own heart is either removed (orthotopic procedure) or, less commonly, left in place to support the donor heart (heterotopic procedure). Post-operation survival periods average 15 years. Heart transplantation is not considered to be a cure for heart disease, but a life-saving treatment intended to improve the quality of life for recipients]]> Sun, 01 Feb 2015 09:38:06 GMT /slideshow/cardiac-transplantation-44128592/44128592 drvishwanathhesarur@slideshare.net(drvishwanathhesarur) Cardiac transplantation drvishwanathhesarur A heart transplant, or a cardiac transplant, is a surgical transplant procedure performed on patients with end-stage heart failure or severe coronary artery disease. As of 2008 the most common procedure is to take a working heart from a recently deceased organ donor (cadaveric allograft) and implant it into the patient. The patient's own heart is either removed (orthotopic procedure) or, less commonly, left in place to support the donor heart (heterotopic procedure). Post-operation survival periods average 15 years. Heart transplantation is not considered to be a cure for heart disease, but a life-saving treatment intended to improve the quality of life for recipients <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/cardiactransplantation-150201093806-conversion-gate02-thumbnail.jpg?width=120&height=120&fit=bounds" /> A heart transplant, or a cardiac transplant, is a surgical transplant procedure performed on patients with end-stage heart failure or severe coronary artery disease. As of 2008 the most common procedure is to take a working heart from a recently deceased organ donor (cadaveric allograft) and implant it into the patient. The patient's own heart is either removed (orthotopic procedure) or, less commonly, left in place to support the donor heart (heterotopic procedure). Post-operation survival periods average 15 years. Heart transplantation is not considered to be a cure for heart disease, but a life-saving treatment intended to improve the quality of life for recipients

Cardiac transplantation from Vishwanath Hesarur

]]> 22948 25 https://cdn.slidesharecdn.com/ss_thumbnails/cardiactransplantation-150201093806-conversion-gate02-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Truncus Arteriosus /slideshow/truncus-arteriosus-44128394/44128394 truncusarteriosus1-150201092726-conversion-gate01
Persistent truncus arteriosus (or patent truncus arteriosus), also known as Common arterial trunk, is a rare form of congenital heart disease that presents at birth. In this condition, the embryological structure known as the truncus arteriosus fails to properly divide into the pulmonary trunk and aorta. This results in one arterial trunk arising from the heart and providing mixed blood to the coronary arteries, pulmonary arteries, and systemic circulation]]>
Persistent truncus arteriosus (or patent truncus arteriosus), also known as Common arterial trunk, is a rare form of congenital heart disease that presents at birth. In this condition, the embryological structure known as the truncus arteriosus fails to properly divide into the pulmonary trunk and aorta. This results in one arterial trunk arising from the heart and providing mixed blood to the coronary arteries, pulmonary arteries, and systemic circulation]]> Sun, 01 Feb 2015 09:27:26 GMT /slideshow/truncus-arteriosus-44128394/44128394 drvishwanathhesarur@slideshare.net(drvishwanathhesarur) Truncus Arteriosus drvishwanathhesarur Persistent truncus arteriosus (or patent truncus arteriosus), also known as Common arterial trunk, is a rare form of congenital heart disease that presents at birth. In this condition, the embryological structure known as the truncus arteriosus fails to properly divide into the pulmonary trunk and aorta. This results in one arterial trunk arising from the heart and providing mixed blood to the coronary arteries, pulmonary arteries, and systemic circulation <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/truncusarteriosus1-150201092726-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds" /> Persistent truncus arteriosus (or patent truncus arteriosus), also known as Common arterial trunk, is a rare form of congenital heart disease that presents at birth. In this condition, the embryological structure known as the truncus arteriosus fails to properly divide into the pulmonary trunk and aorta. This results in one arterial trunk arising from the heart and providing mixed blood to the coronary arteries, pulmonary arteries, and systemic circulation

Truncus Arteriosus from Vishwanath Hesarur

]]> 13646 7 https://cdn.slidesharecdn.com/ss_thumbnails/truncusarteriosus1-150201092726-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 https://public.slidesharecdn.com/v2/images/profile-picture.png https://cdn.slidesharecdn.com/ss_thumbnails/treatmentstrategiesinpatientswithstatinintolerance-150402065028-conversion-gate01-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/treatment-strategies-in-patients-with-statin-intolerance/46574534 Treatment strategies i... https://cdn.slidesharecdn.com/ss_thumbnails/theagecreatinineandejectionfractionscoretorisk-150402065013-conversion-gate01-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/the-age-creatinine-and-ejection-fraction-score-to-risk/46574526 The age, creatinine, a... https://cdn.slidesharecdn.com/ss_thumbnails/riociguatforthetreatmentofpah-150402064955-conversion-gate01-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/riociguat-for-the-treatment-of-pah/46574510 Riociguat for the trea...